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Abstract
Background: Cancer is a major public health concern globally and chemotherapy remains the principal mode of
the treatment of various malignant diseases.
Methods: This study was designed to investigate the cytotoxicity of 14 naturally occurring quinones including; 3
anthraquinones, 1 naphthoquinone and 10 benzoquinones against 6 human carcinoma cell lines and normal
CRL2120 fibroblasts. The neutral red uptake (NR) assay was used to evaluate the cytotoxicity of the compounds,
whilst caspase-Glo assay was used to detect caspases activation. Cell cycle and mitochondrial membrane potential
(MMP) were all analyzed via flow cytometry meanwhile levels of reactive oxygen species (ROS) were measured by
spectrophotometry.
Results: Anthraquinone: emodin (2), naphthoquinone: plumbagin (4), and benzoquinones: rapanone (9), 2,5-dihydroxy-3-
pentadecyl-2,5-cyclohexadiene-1,4-dione (10), 5-O-methylembelin (11), 1,2,4,5-tetraacetate-3-methyl-6-(14-nonadecenyl)-
cyclohexadi-2,5-diene (13), as well as doxorubicin displayed interesting activities with IC50 values below 100 μM in the six
tested cancer cell lines. The IC50 values ranged from 37.57 μM (towards breast adenocarcinoma MCF-7 cells) to 99.31 μM
(towards small cell lung cancer A549 cells) for 2, from 0.06 μM (MCF-7 cells) to 1.14 μM (A549 cells) for 4, from 2.27 μM
(mesothelioma SPC212 cells) to 46.62 μM (colorectal adenocarcinoma DLD-1 cells) for 9, from 8.39 μM (SPC212 cells) to
48.35 μM (hepatocarinoma HepG2 cells) for 10, from 22.57 μM (MCF-7 cells) to 61.28 μM (HepG2 cells) for 11, from 9.
25 μM (MCF-7 cells) to 47.53 μM (A549 cells) for 13, and from 0.07 μM (SPC212 cells) to 1.01 μM (A549 cells) for
doxorubicin. Compounds 4 and 9 induced apoptosis in MCF-7 cells mediated by increased ROS production and MMP
loss, respectively.
Conclusion: The tested natural products and mostly 2, 4, 9, 10, 11 and 13 are potential cytotoxic compounds that deserve
more investigations towards developing novel antiproliferative drugs against human carcinoma.
Keywords: Carcinoma, cytotoxicity, Mode of action, Plumbagin, Quinones, Rapanone
* Correspondence: kuetevictor@yahoo.fr
1Department of Biochemistry, Faculty of Science, University of Dschang,
Dschang, Cameroon
4Department of Biology, Science Faculty, Anadolu University, Eskişehir, Turkey
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kuete et al. BMC Pharmacology and Toxicology  (2016) 17:60 
DOI 10.1186/s40360-016-0104-7
Background
Cancer is a major public health problem globally killing
about 3500 million people and representing 2–3% of the
annual deaths [1]. Due to limited resources and other
pressing public health problems, including communic-
able diseases such as acquired immune deficiency
syndrome (AIDS), malaria, and tuberculosis, cancer con-
tinues to receive low public health priority in Africa,
despite the growing burden of the disease [2]. Chemo-
therapy remains the principal mode of the treatment of
various malignant diseases. In recent years, the search of
antineoplastic compounds of natural origin has become
more and more important. Many investigations are
being carried out to identify new drugs or to find new
lead structures from the flora of Africa to develop novel
therapeutic agents for the treatment of human diseases
such as cancer [3]. In our continous quest of lead mole-
cules to fight cancer, we designed the present study to
investigate the cytotoxicity of 14 quinones including 3
anthraquinones, one naphthoquinone and 10 benzoqui-
nones, previously isolated from African medicinal plants.
The study was extended to the study of the mode of ac-
tion of the most active compounds including; plumbagin
(4; a naphthoquinone) and rapanone (9; a benzoquin-
one). Quinones are secondary metabolites isolated prin-
cipally from plants and having an aromatic di-one or
di-ketone systems. Naturally occurring quinones are
widely distributed and include benzoquinones, naphtho-
quinones, anthraquinones and polyquinones [4]. They
exhibit numerous biological activities such as; neuro-
logical, antibacterial, antiplasmodial, antioxidant, trypa-
nocidal, antitumor, antiviral activities [4, 5]. Amongst
plant secondary metabolites, quinones comprise the
second largest class of anticancer agents [6]. Some qui-
nones isolated from African medicinal plants previously
displayed anticancer activities. They include sarga-
quinoic acid isolated from Sargassum heterophyllum
[7], 2-acetylfuro-1,4-naphthoquinone isolated from
Newbouldia laevis [8], and anthraquinones such as
damnacanthal, damnacanthol, 3-hydroxy-2-hydroxymethyl




The quinones (Fig. 1) used in this study were obtained
from the chemical bank of the natural products research
laboratory of the Chemistry Department, University of
Nairobi, Kenya. Their isolation and identification were
previously reported from the following plants: Rumex
dentatus, R. abyssinicus, R. usambarensis, R. bequaertii,
R. ruwenzoriensis, R. crispus; Plumbago zeylanica,
Myrsine Africana, Maesa lanceolata, Rapanea melanph-
loes, Aloe saponaria [10]. They include anthraquinones:
chrysophanol (1), emodin (2), 3,6,8-trihydroxy-1-methy-
lanthraquinone-2-carboxylic acid methyl ester (3), a
naphthaquinone: 5-hydroxy-2-methyl-1,4-naphthalene-





3-tridecyl-2,5-cyclohexadiene-1,4-dione or rapanone (9),
2,5-dihydroxy-3-pentadecyl-2,5-cyclohexadiene-1,4-dione
(10), 2-hydroxy-5-methoxy-3-undecyl-1,4-benzoquinone
or 5-O-methylembelin (11), 2,5 dimethoxy-6-(14-nonade-
cenyl)-1,4-benzoquinone (12), 1,2,4,5-tetraacetate-3-me-
thyl-6-(14-nonadecenyl)-cyclohexadi-2,5-diene (13) and
ardisiaquinone B (14) [10]. Doxorubicin 98.0% was
purchased from Sigma-Aldrich (Munich, Germany) and
used as reference drug.
Cell lines and culture
Six human cancer cell lines and one normal cell line
were used in this study. They included A549 human
non-small cell lung cancer (NSCLC) cell line, obtained
from the Institute for Fermentation, Osaka (IFO, Japan)
and provided by Prof. Dr. Tansu Koparal (Anadolu
University, Eskisehir, Turkey), SPC212 human mesotheli-
oma cell line obtained from American Type Culture Col-
lection (ATCC) and provided by Dr. Asuman Demiroğlu
Zergeroğlu (Gebze Technical University, Kocaeli, Turkey),
DLD-1 colorectal adenocarcinoma cell lines obtained
from ATCC (CCL-221), Caco2 colorectal adenocarcinoma
cells (ATCC, HTB-37) obtained from the ŞAP Institute of
Turkey (Ankara), HepG2 hepatocarcinoma cells (ATCC,
HB-8065) and MCF-7 breast adenocarcinoma cells
(ATCC, HTB-22) were provided by Prof. Dr. Tansu
Koparal (Anadolu University, Eskisehir, Turkey). The nor-
mal CRL2120 human skin fibroblasts were obtained from
ATCC [CCD1094Sk (ATCC, CRL-2120)]. The cells were
maintained as a monolayer in DMEM medium (Sigma-al-
drich, Munich, Germany) medium supplemented with
10% fetal calf serum and 1% penicillin (100 U/mL)-
streptomycin (100 μg/mL) in a humidified 5% CO2 atmos-
phere at 37 °C.
Neutral red (NR) uptake assay
The cytotoxicity of samples was performed by NR
uptake assay as previously described [11, 12]. This
method is based on the ability of viable cells to incorpor-
ate and bind the supravital dye NR in the lysosomes.
The procedure is cheaper and more sensitive than other
cytotoxicity tests [13]. Samples were added in the culture
medium so that dimethylsufoxide (DMSO) used prior
for dilution did not exceed 0.1% final concentration.
Briefly, cells were detached by treatment with 0.25%
trypsin/EDTA (Invitrogen) and an aliquot of 1 × 104 cells
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was placed in each well of a 96-well cell culture plate
(Thermo Scientific, Germany) in a total volume of
200 μL. The cells were allowed to attach overnight and
subsequently treated with different concentrations of the
14 compounds. Each of the studied samples was imme-
diately added in varying concentrations in additional
100 μL of culture medium to obtain a total volume of
200 μL/well. After 72 h incubation in humidified 5%
CO2 atmosphere at 37 °C, the medium was removed and
200 μL fresh medium containing 50 μg/mL NR was
added to each well and incubation continued for an
additional 3 h at 37 °C in 5% CO2 atmosphere. The dye
medium was then removed and each well was then
washed rapidly with 200 μL phosphate buffer saline
(PBS) followed by addition of 200 μL of acetic acid-
water-ethanol in water (1:49:50). The plates were kept
for 15 min at room temperature to extract the dye and
then shaken for a few minutes on a GFL 3012 shaker
(Gesellschaft für Labortechnik mbH, Burgwedel,
Germany). Absorbance was measured on ELx 808 Ultra
Microplate Reader (Biotek) equipped with a 540 nm
filter. Each assay was done at least three times, with
three replicates each. The viability was evaluated based
on a comparison with untreated cells. The IC50 values rep-
resent the sample’s concentrations required to inhibit 50%
of cell proliferation and were calculated from a calibration
curve by linear regression using Microsoft Excel [14].
Flow cytometry for cell cycle analysis and detection of
apoptotic cells
The cell-cycle analysis was performed by flow cytometry
using BD cycletestTM Plus DNA Kit Assay (BD Biosci-
ences, San Jose, USA). The BD Cycletest™ Plus DNA kit
provides a set of reagents for isolating and staining cell
nuclei. Flow cytometric analysis of differentially stained
cells is used to estimate the DNA index (DI) and cell-
cycle phase distributions. Briefly, MCF-7 cells (3 mL,
1 × 105 cells/mL) were seeded into each well of 6-well
plates and allowed to attach for 24 h. The cells which
were treated with ¼ × IC50, ½ × IC50 and IC50 concentra-
tions of compounds 4, 9 and the standard drug, doxo-
rubicin were then grown in 6-well plates for 72 h. The
untreated cells (control) were also included in the assay.
They were further trypsinized and suspended in 1 mL
Fig. 1 Chemical structures of the tested compounds. Chrysophanol (1), emodin (2), 3,6,8-trihydroxy-1-methylanthraquinone-2-carboxylic acid methyl
ester (3), a naphthaquinone; 5-hydroxy-2-methyl-1,4-naphthalenedione or plumbagin (4), benzoquinones; 2,5-dihydroxy-3-ethyl-2,5-cyclohexadiene-
1,4-dione (5), 2,5-dihydroxy-3-propyl-2,5-cyclohexadiene-1,4-dione (6), 2,5-dihydroxy-3-butyl-2,5-cyclohexadiene-1,4-dione (7), 2,5-dihydroxy-3-heptyl-
2,5-cyclohexadiene-1,4-dione (8), 2,5-dihydroxy-3-tridecyl-2,5-cyclohexadiene-1,4-dione or rapanone (9), 2,5-dihydroxy-3-pentadecyl-2,5-cyclohexadiene-
1,4-dione (10), 2-hydroxy-5-methoxy-3-undecyl-1,4-benzoquinone, 5-O-methylembelin (11), 2,5 dimethoxy-6-(14-nonadecenyl)-1,4-benzoquinone (12),
1,2,4,5-tetraacetate-3-methyl-6-(14-nonadecenyl)-cyclohexadi-2,5-diene (13), ardisiaquinone B (14)
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PBS, then centrifuged at 400 g for 5 min at room
temperature (RT). The cells were further processed ac-
cording to the manufacturer protocol: addition of
250 μL of solution A (trypsin buffer), 10 min incubation
at RT followed by the addition of 200 μL of solution B
(trypsin inhibitor and RNAse buffer), 10 min incubation
at RT followed by the addition of 200 μL of solution C
(2–8 °C) (propidium iodide stain solution), 10 min on
ice. The cells were further measured on a BD FACS Aria I
Cell Sorter Flow Cytometer (Becton-Dickinson,
Germany). For each sample, 104 cells were counted. For
PI excitation, an argon-ion laser emitting at 488 nm was
used. Cytographs were analyzed using BD FACSDiva™
Flow Cytometry Software Version 6.1.2 (Becton-
Dickinson).
Caspase-Glo 3/7 and caspase-Glo 9 assay
Caspases activity in MCF-7 cells was detected using
Caspase-Glo 3/7 and Caspase-Glo 9 Assay kits
(Promega, Mannheim, Germany) as previously reported
[15–17]. Cells were treated with compounds 4 and 9 at
their 2 × IC50 and IC50 values with DMSO as solvent
control for 6 h. Luminescence was measured using an
BioTek Synergy™ HT multi-detection microplate reader.
Caspase activity was expressed as percentage of the
untreated control.
Analysis of mitochondrial membrane potential (MMP)
The MMP was analyzed in MCF-7 cells by 5,5′,6,6′-tet-
rachloro-1,1′,3,3′-tetraethylbenzimidazolylcarbocyanine
iodide) (JC-1; Biomol, Hamburg, Germany) staining as
previously reported [15–17]. Cells (3 mL, 1 × 105 cells/
mL) treated for 72 h with different concentrations (¼ ×
IC50, ½ × IC50 and IC50) of compounds 4, 9 and doxo-
rubicin (drug control) or DMSO (solvent control) were
incubated with JC-1 staining solution for 30 min accord-
ing to the manufacturer’s protocol as reported in earlier.
Subsequently, cells were measured in a BD FACS Aria I
Cell Sorter Flow Cytometer (Becton-Dickinson,
Germany). The JC-1 signal was measured at an excita-
tion of 561 nm (150 mW) and detected using a 586/
15 nm band-pass filter. The signal was analyzed at
640 nm excitation (40 mW) and detected using a 730/
45 nm bandpass filter. Cytographs were analyzed using
BD FACSDiva™ Flow Cytometry Software Version 6.1.2
(Becton-Dickinson). All experiments were performed at
least in triplicate.
Measurement of reactive oxygen species (ROS)
The 2′,7′-dichlorodihydrofluorescein diacetate (H2DCFH-
DA) (Sigma-Aldrich) was used for the detection of ROS in
MCF-7 cells treated with compounds 4, 9 and doxorubi-
cin (drug control) or DMSO (solvent control) using Oxi-
Select™ Intracellular ROS Assay Kit (Green Fluorescence)
as recommended by the manufacturer, Cell Biolabs Inc.
(San Diego, USA). This is a cell-based assay for measuring
hydroxyl, peroxyl, or other reactive oxygen species activity
within a cell. The assay employs the cell-permeable fluoro-
genic probe 2′,7′-dichlorodihydrofluorescin diacetate
(DCFH-DA). DCFH-DA is diffused into cells and is
deacetylated by cellular esterases to non-fluorescent
2′,7′-dichlorodihydrofluorescin (DCFH), which is rapidly
oxidized to highly fluorescent 2′,7′-dichlorofluorescein
(DCF) by ROS. Cells (1 × 104 cells) were treated with sam-
ples at ¼ × IC50, ½ × IC50 and IC50 for 24 h. After addition
of 100 μL 1× DCFH-DA/DMEM solution to cells and in-
cubation at 37 °C for 30–60 min, the fluorescence was
measured using SpectraMax® M5 Microplate Reader
(Molecular Devices, Biberach, Germany) at 480/530 nm.
All experiments were performed at least in triplicate.
Results
The fourteen investigated compounds included three an-
thraquinones; chrysophanol C15H10O4 (1; m/z: 254.0579),
emodin C15H10O5 (2; m/z: 270.0528), 3,6,8-trihydroxy-1-
methylanthraquinone-2-carboxylic acid methyl ester C17H
12O7 (3; m/z: 328.0583), one naphthaquinone; 5-hydroxy-2-
methyl-1,4-naphthalenedione or plumbagin C11H8O3 (4;
m/z: 188.0473), and benzoquinones; 2,5-dihydroxy-3-ethyl-
2,5-cyclohexadiene-1,4-dione C8H8O4 (5; m/z: 168.0423),
2,5-dihydroxy-3-propyl-2,5-cyclohexadiene-1,4-dione C9H
10O4 (6; m/z: 182.0579), 2,5-dihydroxy-3-butyl-2,5-cyclo-
hexadiene-1,4-dione C10H12O4 (7; m/z: 196.0736), 2,5-dihy-
droxy-3-heptyl-2,5-cyclohexadiene-1,4-dione C13H18O4 (8;
m/z: 238.1205), 2,5-dihydroxy-3-tridecyl-2,5-cyclohexa-
diene-1,4-dione or rapanone C19H30O4 (9; m/z: 332.4450),
2,5-dihydroxy-3-pentadecyl-2,5-cyclohexadiene-1,4-dion
e C21H34O4 (10; m/z: 350.2457), 2-hydroxy-5-methoxy-3-
undecyl-1,4-benzoquinone, 5-O-methylembelin C18H28O4
(11; m/z: 308.1988), 2,5 dimethoxy-6-(14-nonadecenyl)-1,4-
benzoquinone C27H44O4 (12; m/z: 432.3240), 1,2,4,5-tetraa-
cetate-3-methyl-6-(14-nonadecenyl)-cyclohexadi-2,5-diene
C34H54O8 (13; m/z: 590.3819), ardisiaquinone B C30H40O8
(14; m/z: 528.2723) [10]. These compounds are available in
the Chemical bank of the Department of Chemistry,
University of Nairobi, Kenya.
Cytotoxicity
The cytotoxicity of the 14 quinones and doxorubicin
was determined by the NR uptake assay and the
recorded IC50 values are summarized in Table 1. The
selectivity index was determined as the ratio of IC50
value in the CRL2120 normal fibroblast divided by the
IC50 in the cancer cell line. Compounds 2, 4, 9, 10, 11
and 13 as well as doxorubicin displayed IC50 values
below 100 μM in the six tested cancer cell lines. Com-
pounds 3, 5 and 12 were not active with IC50 values
above 120 μM in all cancer cell lines meanwhile 1, 6, 7,
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Table 1 Cytotoxicity of tested compounds and doxorubicin towards cancer cell lines and normal cells as determined by the neutral red assay
Compounds Cell lines, IC50 values in μM and selectivity indexa (in bracket)
A549 SPC212 DLD-1 Caco-2 MCF-7 HepG2 CRL2120
1 52.24 ± 5.51 (>3.01) 145.63 ± 10.63 (>1.08) >157.48 >157.48 >157.48 >157.48 >157.48
2 66.30 ± 6.19 (>2.23) 99.31 ± 8.46 (>1.49) 77.28 ± 8.77 (>1.92) 73.63 ± 3.52 (>2.01) 37.57 ± 2.59 (>3.94) 71.7 ± 4.52 (>2.07) >148.15
3 >121.95 >121.95 >121.95 >121.95 >121.95 >121.95 >121.95
4 1.14 ± 0.02 (59.35) 0.27 ± 0.01 (250.59) 0.98 ± 0.11 (70.47) 0.07 ± 0.01 (966.57) 0.06 ± 0.01 (1127.67) 1.01 ± 0.08 (66.99) 67.66 ± 6.49
5 >238.10 >238.10 >238.10 >238.10 >238.10 >238.10 95.51 ± 5.64
6 >222.22 >222.22 >222.22 >222.22 161.92 ± 11.37 >222.22 >222.22
7 68.62 ± 7.55 ((>2.97) 87.91 ± 5.66 (2.32) >204.08 89.72 ± 8.80 (>2.27) 64.59 ± 13.42 (>3.16) 176.17 ± 28.5 (>1.16) >204.08
8 107.52 ± 17.95 (1.09) 8.05 ± 1.46 (1.09) >168.07 63.93 ± 5.97 (2.27) 38.8 ± 3.33 (3.16) 94.22 ± 2.7 (1.16) 117.27 ± 1.22
9 27.35 ± 1.46 (3.48) 2.27 ± 1.52 (41.96) 46.62 ± 5.38 (2.04) 22.95 ± 0.13 (4.15) 16.94 ± 4.65 (5.62) 32.69 ± 0.61 (2.91) 95.24 ± 6.65
10 43.32 ± 2.72 (>2.87) 8.39 ± 0.48 (>14.81) 51.21 ± 5.54 (>2.43) 27.81 ± 2.03 (>4.47) 30.37 ± 8.64 (>4.09) 48.35 ± 3.73 (>2.57) >124.24
11 50.26 ± 2.60 (0.88) 38.28 ± 3.23 (1.15) 45.37 ± 4.89 (0.97) 38.89 ± 2.35 (1.14) 22.56 ± 1.57 (1.96) 61.28 ± 5.53 (0.72) 44.20 ± 0.2
12 >129.45 >129.45 >129.45 >129.45 >129.45 >129.45 >129.45
13 47.53 ± 3.56 (1.96) 36.21 ± 3.08 (2.57) 25.09 ± 1.50 (3.72) 24.63 ± 2.71 (3.78) 9.25 ± 0.16 (10.08) 18.17 ± 1.46 (5.13) 93.21 ± 1.17
14 21.68 ± 1.50 (3.29) 3.14 ± 0.78 (22.72) 114.17 ± 3.68 (0.62) >123.08 >123.08 114.60 ± 4.29 (0.62) 71.34 ± 5.23
Doxorubicin 1.01 ± 0.19 (0.58) 0.07 ± 0.01 (8.43) 0.37 ± 0.05 (1.59) 0.72 ± 0.13 (0.82) 0.35 ± 0.05 (1.69) 0.18 ± 0.03 (3.28) 0.59 ± 0.01
(a): The selectivity index was determined as the ratio of IC50 value in the CRL2120 normal fibroblasts divided by the IC50 in the cancer cell lines. Chrysophanol (1), emodin (2), 3,6,8-trihydroxy-1-methylanthraquinone-2-
carboxylic acid methyl ester (3), plumbagin (4), 2,5-dihydroxy-3-ethyl-2,5-cyclohexadiene-1,4-dione (5), 2,5-dihydroxy-3-propyl-2,5-cyclohexadiene-1,4-dione (6), 2,5-dihydroxy-3-butyl-2,5-cyclohexadiene-1,4-dione (7), 2,5-
dihydroxy-3-heptyl-2,5-cyclohexadiene-1,4-dione (8), 2,5-dihydroxy-3-tridecyl-2,5-cyclohexadiene-1,4-dione or rapanone (9), 2,5-dihydroxy-3-pentadecyl-2,5-cyclohexadiene-1,4-dione (10), 2-hydroxy-5-methoxy-3-undecyl-1,4-
benzoquinone, 5-O-methylembelin (11), 2,5 dimethoxy-6-(14-nonadecenyl)-1,4-benzoquinone (12), 1,2,4,5-tetraacetate-3-methyl-6-(14-nonadecenyl)-cyclohexadi-2,5-diene (13), ardisiaquinone B (14). In bold: significant activity














8, and 14 displayed selective activities. The recordable
IC50 values were obtained in 1/6 tested cancer cell lines
for 6, 2/6 for 1, 4/6 for 14 and 5/6 for 7 and 8. Concern-
ing the most active compounds, IC50 values ranged from
37.57 μM (towards breast adenocarcinoma MCF-7 cells)
to 99.31 μM (towards small cell lung cancer A549 cells)
for 2, from 0.06 μM (towards MCF-7 cells) to 1.14 μM
(against A549 cells) for 4, from 2.27 μM (towards meso-
thelioma SPC212 cells) to 46.62 μM (against colorectal
adenocarcinoma DLD-1 cells) for 9, from 8.39 μM
(towards SPC212 cells) to 48.35 μM (towards hepatocar-
inoma HepG2 cells) for 10, from 22.57 μM (towards
MCF-7 cells) to 61.28 μM (towards HepG2 cells) for 11,
from 9.25 μM (against MCF-7 cells) to 47.53 μM
(against A549 cells) for 13, and from 0.07 μM (towards
SPC212 cells) to 1.01 μM (towards A549 cells) for doxo-
rubicin. The six most active compounds (2, 4, 9, 10 and
13) were generally less toxic towards normal CRL2120
fibroblast than carcinoma cells, and the obtained select-
ivity indexes were above 1.49, 1.96, 2.51, 2.91 and 59, re-
spectively for 2, 13, 10, 9 and 4. Nonetheless, 11 as well
as doxorubicin were in many cases slightly more toxic
on normal CRL2120 fibroblast than on cancer cells
(Table 1). Two compounds having the lowest IC50
values, namely 4 (below or around 1 μM in all the six
cancer cell lines) and 9 (lowest IC50 value of 2.27 μM
towards SPC212 cells) as well as doxorubicin were tested
for the effects on cell cycle distribution, caspases activity,
MMP breakdown and ROS production in MCF-7 cells.
Cell cycle analysis and apoptosis
Naphthoquinone 4 and benzoquinone 9 were analyzed
for their ability to alter the distribution of the cell cycle
of MCF-7 breast cancer cells (Fig. 2). It was observed
that the two compounds induced concentration-
dependent cell cycle modifications with progressive
increase of sub-G0/G1 phase cells. Compounds 4 and 9
induced cell cycle arrest between G0/G1 and S phases.
MCF-7 cells treated with the compounds 4 and 9 pro-
gressively underwent apoptosis, with increase of sub-G0/
G1 cells from 10.4% (¼ IC50) to 20.4% (IC50) for 4 and
from 34.8% (¼ IC50) to 43.2% (IC50) for 9. The positive
control, doxorubicin also caused up to 60% sub-Go/G1
phase with IC50 treatment in comparison to only 3.1% in
non-treated cells.
Caspases activities
Upon treatment of MCF-7 cells with naphthoquinone
4 and benzoquinone 9 with equivalent (eq.) to the
IC50 and 2-fold IC50 for 6 h, no modification of the
activity of caspase 3/7 and caspase 9 was observed
(data not shown).
Fig. 2 Effects of plumbagin (4), rapanone (9), and doxorubicin on cell cycle distribution in MCF-7 cells. IC50 values were 0.06 μM (4), 16.94 (9) and
0.35 μM (doxorubicin)
Kuete et al. BMC Pharmacology and Toxicology  (2016) 17:60 Page 6 of 10
MMP breakdown
Treatment of MCF-7 cells with compounds 4 and 9
with eq. to the 1/4 × IC50, 1/2 × IC50 and IC50 values
for 72 h induced concentration-dependent depletion
of MMP (Fig. 3). More pronounced effect was ob-
served with 9 with up to 88.1% depletion of MMP at
eq. to IC50 while 4 caused 12.2% MMP loss at IC50.
In similar experimental condition, doxorubicin caused
26% loss of MMP meanwhile only 4.3% was observed
with non-treated control.
ROS production
After treatment of MCF-7 cells with naphthoquinone 4 and
benzoquinone 9 at eq. to the 1/4 × IC50, 1/2 × IC50 and IC50
values for 24 h, the production of ROS in cells was analyzed
(Fig. 4). Naphthoquinone 4 induced increased ROS levels
of more than 3-fold (at IC50) as compared with non-treated
cells meanwhile the increase was lesser (less than 2-fold)
after treatment with benzoquinone 9. In similar experimen-
tal condition doxorubicin also induced more than 2-fold in-
crease in ROS production in MCF-7 cells at eq. to IC50.
Fig. 3 Effects of plumbagin (4), rapanone (9), and doxorubicin on MMP in MCF-7 cells for 72 h. IC50 values were 0.06 μM (4), 16.94 (9) and
0.35 μM (doxorubicin). Cells were treated with ¼ × IC50 (C1), ½ × IC50 (C2) and IC50 (C3) of each compound
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Discussion
Neoplastic diseases are one of the leading causes of mor-
tality worldwide and the number of cancer cases are in-
creasing regularly [1]. In general, leukemia cells are
clinically more sensitive to chemotherapy than tumors
[18, 19]. In the present study we focused on carcinoma
cells involved in lung, colon, breast and liver cancers. In
regards of the broad diversity of phytochemicals, the
search of anticancer agents from plants represents an at-
tractive strategy [20]. Molecules having IC50 values
around or below 4 μg/mL or 10 μM [3, 21, 22] have
been recognized as potential cytotoxic substances. IC50
values below 10 μM were observed with naphthoqui-
none 4 in all the six cancer cell lines. Interestingly, IC50
values below 1 μM were obtained with this compound
in 4 of the 6 cancer cell lines, highlighting its good cyto-
toxic potential. In addition, the IC50 values obtained with
4 towards Caco-2 cells and MCF-7 cells were lower than
that of the reference compound, doxorubicin. Other
compounds such as 8, 9 and 10 against SPC212 cells as
well as 13 towards MCF-7 also displayed IC50 values
below 10 μM, suggesting that they can be useful in the
management of human carcinoma. Moreover, they were
more toxic towards carcinoma cells than towards normal
CRL2120 fibroblast (selectivity index > 1), indicating
their good selectivity. The good activity obtained with
naphthoquinone 4 is in accordance with previous stud-
ies. In fact, 2-acetylfuro-1,4-naphthoquinone previously
displyed good cytotoxicity with IC50 values below 10 μM
against a panel of cancer cell lines such as PF-382
leukemia T-cells, MiaPaCa-2 pancreatic cells, U87MG
glioblastoma-astrocytoma cells, Colo-38 skin melanoma
cells, HeLa and Caski cervical carcinoma cells [8]. Also,
compound 4 is well known for its remarkable anticancer
activities [6]. The present study therefore provides
additional data on the anticancer potential of this
compound and highlights the role of naphthoquinones
as good cytotoxic compounds. The moderate cytotoxic
effects of some anthraquinones such as damnacanthal,
damnacanthol, 3-hydroxy-2-hydroxymethyl anthraquin-
one and schimperiquinone B on a panel of cancer cell
lines was documented [9]. In the present study, the
moderate to low activities obtained with anthraquinones
1–3 are also in accordance with such results. Induction
of apoptosis is recognized as an efficient strategy for
cancer chemotherapy and a useful indicator for cancer
treatment and prevention. In the present study, it was
found that compounds 4 and 9 induced apoptosis in
MCF-7 cells (Fig. 2). Hence, further investigations of the
mode of induction of apoptosis were performed. Cas-
pases regulate apoptosis by cleaving cellular proteins at
specific aspartate residues [23]. The activity of initiator
caspase 9 and effector caspases 3/7 were investigated in
MCF-7 cells treated with 4 and 9. However, it was found
that caspase-dependent cell death may not be one of the
pathways of induction of apoptosis by 4 and 9 in MCF-7
cells. Loss of MMP is also classical evidence for apop-
tosis, occuring during the early stage of apoptosis before
the cell morphology changes. The disruption of MMP
was suggested to be very strong at percentages above
50%, and strong between 20 and 50% [3]; Up to 88.1%
(at IC50) MMP depletion was obtained, when MCF-7
cells were treated with IC50 concentrations of 9, suggest-
ing that MMP depletion is involved in apoptotic path-
way induced by this compound. ROS levels between 20
and 50% are considered as high [3]; More than 3-fold in-
crease in ROS production was also obtained as results of
treatment of MCF-7 with compound 4. However, only
12.2% MMP depletion was obtained with this com-
pound, suggesting that increase in ROS production the
likely mode of apoptosis induced by naphthoquinone 4.
The tetraprenylquinone, sargaquinoic acid was shown to
Fig. 4 Induction of ROS in MCF-7 cells after treatment with plumbagin (4), rapanone (9), and doxorubicin for 24 h. IC50 values were 0.06 μM (4),
16.94 (9) and 0.35 μM (doxorubicin). Cells were treated with ¼ × IC50 (C1), ½ × IC50 (C2) and IC50 (C3) of each compound
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induce cycle arrest in MDA-MB-231 cells and apoptosis
via increase in the activities of caspases 3, 6, 8, 9 and 13
[7]. However, it was demonstrated in this study that the
related compound 9 induced apoptosis mediated by
MMP loss but did not induced increase in the activity of
caspases 3 and 9. Herein, it was also shown that com-
pound 4 induced MMP loss in MCF-7 cells. Nonethe-
less, the induction was moderate. Compound 4 was also
reported to induce apoptosis in PC-3 and DU145 cells,
mediated by MMP loss [24]; this corroborates the results
obtained in this work.
Regarding the structure-activity relationship, it appears
that the naphthoquinone 4 was more potent in all six
tested cancer cell lines than anthraquinones (1–5) and
benzoquinone (5–14). Within anthraquinones, the sub-
stitution of hydroxyl (−OH) group in C8 (1 and 2) by a
methyl group (3) significantly reduced the cytotoxic
activity meanwhile the presence of −OH group in both
C8 and C6 (2) seems to increase the activity. Conse-
quently, IC50 values were obtained with 2 on all tested
cancer cells lines and 1 on 2/6 (Table 1). Within benzo-
quinones, the degree of activity seems to increase with
the size of the lateral chain in C2, the best effects being
obtained between n = 10 (11) to n = 14 (10). However,
compound 9 with n = 12 displayed better cytotoxic
effects than 10 and 11 in all tested cancer cell lines
(Table 1), most probably because of its higher
lipophilicity.
Conclusions
Finally, we demonstrated the cytotoxicity of naturally
occuring quinones against human carcinoma cell lines.
Naphthoquione 4 as well as anthraquinone 2 and benzo-
quinones 9, 10, 11, and 13 displayed cytotoxic effects on
all tested cancer cell lines. Compounds 4 and 9 induced
apoptosis in MCF-7 cells mediated by increase ROS pro-
duction and MMP loss repectively. The studied com-
pounds and especially the most active ones deserve
more investigations to develop novel cytotoxic drugs
against cancers.
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